Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02899299 · ClinicalTrials.gov registry record · Phase 3

Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

A Phase 3 study, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 3
Development phase
605
Enrollment target

NCT02899299: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.

NCT02899299 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 605 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02899299, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 3
Development phase
605 participants
Enrollment target

Study Summary

The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.

Primary Outcome

Overall Survival was defined as the time from randomization to the date of death due to any cause. A participant who has not died was censored at last known date alive.

Interventions

  • DRUG Carboplatin
  • DRUG Cisplatin
  • DRUG Pemetrexed
  • BIOLOGICAL Nivolumab
  • BIOLOGICAL Ipilimumab

Trial Details

FieldValue
Enrollment Target 605 participants
Start Date 2016-11-29
Est. Completion 2023-04-28
Phase Phase 3
Bristol-Myers Squibb

1,025 total trials

What the finished NCT02899299 record still lists

NCT02899299 is an interventional study that assigns participants to a tested intervention. The registered 605 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower).

The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.

NCT02899299 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02899299 about?

NCT02899299 is a clinical study titled "Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients". The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients with unresectable pleural mesothelioma.

What is the current status of trial NCT02899299?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 605 participants. The study started on 2016-11-29. Estimated completion is 2023-04-28.

What interventions are being tested in trial NCT02899299?

The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT02899299?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT02899299's enrollment target sits among peer trials

605 607th of 2000 higher than 1,394 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02342444 · 606 participants · Phase 4

    Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)

  • NCT03849443 · 604 participants · Early Phase 1

    Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery

  • NCT05238922 · 604 participants · Phase 1

    Study of INCB123667 in Subjects With Advanced Solid Tumors

  • NCT06040541 · 604 participants · Phase 1

    Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02899299, the US trial registry maintained by the National Library of Medicine. NCT02899299 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.